JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Oncogenic K-RAS mutations drive lung adenocarcinoma (AC) but lack direct targeted therapies.
• Targeting downstream pathways, cooperating signals, or tumor-promoting inflammation presents a viable therapeutic strategy.
• The Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is implicated in inflammation-mediated tumorigenesis.

Purpose of the Study:

• To investigate the role of JAK-STAT signaling in K-RAS-driven lung AC.
• To evaluate the therapeutic potential of JAK1/2 inhibition in K-RAS-driven lung AC.

Main Methods:

• Analysis of JAK1 and JAK2 activation in human lung AC tissues.
• Correlation of JAK-STAT signaling activation with disease progression and K-RAS activity.
• Administration of the JAK1/2 inhibitor ruxolitinib in K-RAS-driven lung AC mouse models.
• Assessment of tumor cell proliferation, tumor progression, and tumor microenvironment changes.

Main Results:

• JAK1 and JAK2 were activated in human lung AC, correlating with disease progression and K-RAS activity.
• Ruxolitinib treatment reduced tumor cell proliferation and tumor progression in mouse models.
• JAK1/2 inhibition modulated the tumor microenvironment, decreasing pro-tumorigenic factors and myeloid-derived suppressor cells.

Conclusions:

• JAK-STAT signaling is activated in K-RAS-driven lung AC and linked to disease progression.
• JAK1/2 inhibition, specifically with ruxolitinib, demonstrates therapeutic efficacy against K-RAS-driven lung AC.
• Targeting JAK1/2 offers a promising strategy by modulating the tumor microenvironment and inhibiting tumor growth.